|
|
 |
|
 |
 |
 |
 |
 home |
|
|
|
|
|
| about
pSivida |
|
|
|
|
|
| applications |
|
|
|
|
|
| investor
relations |
|
|
|
|
|
| corporate
governance |
|
|
|
|
|
| nanotechnology |
|
|
|
|
|
| office
locations |
|
|
|
|
|
|
|
|
|
||||||||||||||
|
“Nanotechnology refers to any application of science that deals with elements between 100 nanometres and a tenth of a nanometer in size, in which size is critical to the application’s ultimate purpose.”
This description applies to pSivida’s development of BioSilicon™, which is an example of top-down nanostructuring whereby the element silicon is nanostructured to create nano-pores within the material. The “bridges” of the BioSiliconTM skeleton surrounding these pores are tens of atoms in width. The pores can be loaded with drugs including small molecules, peptides, proteins and vaccines. The size of the pores can be controlled exquisitely during the nanostructuring process. pSivida is involved in new nanotechnology markets that are viewed by Governments and corporate enterprises around the world as extremely important and capable of providing significant economic benefits, particularly in areas such as medicine and healthcare. pSivida’s research and development work in the area of nanomedicine was recently recognized with the prestigious 2004 Frost & Sullivan Excellence in Research Award.
 |
|
|
|
|
nanotechnology
